Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
Objective: BCR-ABL1 kinase domain (KD) mutations can lead to resistance to first- and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Here, we present the first report of the spectrum of mutations in the BCR-ABL1 KD of CML patients from Azerbaijan.Materials and...
Saved in:
Main Authors: | Aypara Hasanova (Author), Chingiz Asadov (Author), Nigar Karimova (Author), Aytan Shirinova (Author), Gunay Aliyeva (Author), Zohra Alimirzoyeva (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chronic Myeloid Leukemia with Rare e1a3 BCR-ABL Transcript
by: Najia Tabassum, et al.
Published: (2024) -
BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran
by: Hossein Ayatollahi, et al.
Published: (2018) -
Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells
by: Yuming Wei, et al.
Published: (2015) -
PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration
by: Rui Su, et al.
Published: (2023) -
BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
by: Gustavo P. Amarante-Mendes, et al.
Published: (2022)